Search

Your search keyword '"Capobianco, Marco"' showing total 424 results

Search Constraints

Start Over You searched for: Author "Capobianco, Marco" Remove constraint Author: "Capobianco, Marco"
424 results on '"Capobianco, Marco"'

Search Results

4. Signs and symptoms of COVID‐19 in patients with multiple sclerosis

7. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

10. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

11. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

12. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

14. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients

15. Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010)

16. Myelin-oligodendrocyte glycoprotein antibody-associated disease

17. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

18. Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

20. Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy.

21. E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

22. E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

23. E.U. paediatric MOG consortium consensus: Part 4 – Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

24. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

25. E.U. paediatric MOG consortium consensus: Part 2 – Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

26. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder

28. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

30. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

31. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

32. Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

33. Profile of serum biomarkers in seronegative NMOSD (S50.009)

34. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients

35. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

36. Sars-CoV2 infection in pregnant women with multiple sclerosis

38. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study

39. Incidence and long-term functional outcome of neurologic disorders in hospitalized COVID-19 patients infected with pre-omicron variants

44. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

45. Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control stud

48. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis

49. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

50. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

Catalog

Books, media, physical & digital resources